Home Stock

Stock Research: Kiniksa Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Kiniksa Pharmaceuticals

NSQ:KNSA GB00BRXB0C07
n/a
  • Value
    10
  • Growth
    100
  • Safety
    Safety
    n/a
  • Combined
    n/a
  • Sentiment
    40
  • 360° View
    360° View
    n/a
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

more
Strongest Rank Dividend Yield
Weakest Rank Growth
Country United Kingdom
Industry Biotechnology
Size Small
Website kiniksa.com
Index
NASDAQ
Kiniksa Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
10 n/a n/a n/a
Growth
100 n/a n/a n/a
Safety
Safety
n/a n/a n/a n/a
Sentiment
40 n/a n/a n/a
360° View
360° View
n/a n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
92 n/a n/a n/a
Opinions Change
31 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
27 n/a n/a n/a
Sentiment
40 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
10 n/a n/a n/a
Growth
100 n/a n/a n/a
Safety Safety
n/a n/a n/a n/a
Combined
n/a n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
31 n/a n/a n/a
Price vs. Earnings (P/E)
26 n/a n/a n/a
Price vs. Book (P/B)
26 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
10 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
86 n/a n/a n/a
Profit Growth
91 n/a n/a n/a
Capital Growth
100 n/a n/a n/a
Stock Returns
95 n/a n/a n/a
Growth
100 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
100 n/a n/a n/a
Refinancing
48 n/a n/a n/a
Liquidity
n/a n/a n/a n/a
Safety Safety
n/a n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Kiniksa Pharmaceuticals and broaden your portfolio horizons.

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Metlen Energy & Metals

LSE:MTLN
Country: United Kingdom
Industry: Industrial Conglomerates
Size: Large
Full Stock Analysis

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: Large
Full Stock Analysis

Bachem

SWX:BANB
Country: Switzerland
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

n/a

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews